Cost Management Insights: SG&A Expenses for AbbVie Inc. and Dr. Reddy's Laboratories Limited

SG&A Expenses: Pharma Giants' Cost Strategies Unveiled

__timestampAbbVie Inc.Dr. Reddy's Laboratories Limited
Wednesday, January 1, 2014772400000038783000000
Thursday, January 1, 2015638700000042585000000
Friday, January 1, 2016585500000045702000000
Sunday, January 1, 2017627500000046372000000
Monday, January 1, 2018739900000046910000000
Tuesday, January 1, 2019694200000048890000000
Wednesday, January 1, 20201129900000050129000000
Friday, January 1, 20211234900000054559000000
Saturday, January 1, 20221526000000062081000000
Sunday, January 1, 202312872000000105931000000
Monday, January 1, 2024077201000000
Loading chart...

Cracking the code

Cost Management Insights: SG&A Expenses for Leading Pharma Giants

In the ever-evolving pharmaceutical industry, effective cost management is crucial for maintaining competitive advantage. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two industry titans: AbbVie Inc. and Dr. Reddy's Laboratories Limited, from 2014 to 2023. Over this period, Dr. Reddy's Laboratories consistently outpaced AbbVie in SG&A spending, with a peak in 2023 where their expenses were nearly 70% higher than AbbVie's. Notably, AbbVie saw a significant increase in 2022, with expenses rising by approximately 24% compared to the previous year. However, 2023 data for AbbVie is missing, leaving a gap in the trend analysis. These insights highlight the strategic financial decisions made by these companies in response to market dynamics and regulatory changes, offering a glimpse into their operational priorities and growth strategies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025